{
    "clinical_study": {
        "@rank": "25272", 
        "brief_summary": {
            "textblock": "To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of PMEA ( adefovir )\n      when administered daily by intravenous (IV) and/or subcutaneous (SC) injection in patients\n      with advanced HIV disease."
        }, 
        "brief_title": "A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive a single IV or SC dose of PMEA daily for 4 weeks. A maximum tolerated dose\n      will be defined for these regimens."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Other antiretroviral therapy IF on a stable dose for at least 4 weeks prior to study\n             entry.\n\n          -  Prophylactic therapy with aerosolized pentamidine, oral trimethoprim/sulfamethoxazole\n             (Bactrim, Septra) or dapsone, and fluconazole or ketoconazole IF on a stable\n             prophylactic regimen for at least 4 weeks prior to study entry.\n\n        Patients must have:\n\n          -  HIV seropositivity.\n\n          -  Elevated p24 antigen (> 40 pg/ml).\n\n          -  Mean CD4 count <= 100 cells/mm3.\n\n          -  Life expectancy of at least 3 months.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Other prior antiretroviral therapy.\n\n          -  Prophylactic therapy with aerosolized pentamidine, oral trimethoprim/sulfamethoxazole\n             (Bactrim, Septra) or dapsone, and fluconazole or ketoconazole.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Inadequate venous access.\n\n          -  Active serious infection (other than HIV infection) requiring parenteral antibiotic\n             therapy.\n\n          -  Clinically significant cardiac disease, including symptoms of ischemia, congestive\n             heart failure, or arrhythmia.\n\n          -  Psychiatric disturbance or illness that may affect compliance.\n\n          -  Malignancy other than Kaposi's sarcoma.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Investigational agents other than stavudine (d4T).\n\n          -  Interferon-alpha.\n\n          -  Ganciclovir.\n\n          -  Foscarnet.\n\n          -  Diuretics.\n\n          -  Amphotericin B.\n\n          -  Aminoglycoside antibiotics.\n\n          -  Other nephrotoxic agents.\n\n          -  Acyclovir at doses >= 2 g/day.\n\n        Prior Medication:\n\n        Excluded within 2 weeks prior to study entry:\n\n          -  Investigational agents other than stavudine (d4T).\n\n          -  Interferon-alpha.\n\n          -  Ganciclovir.\n\n          -  Foscarnet.\n\n          -  Diuretics.\n\n          -  Amphotericin B.\n\n          -  Aminoglycoside antibiotics.\n\n          -  Other nephrotoxic agents.\n\n        Excluded within 4 weeks prior to study entry:\n\n          -  Systemic therapy for Kaposi's sarcoma. Substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "20", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002115", 
            "org_study_id": "217A", 
            "secondary_id": "GS-92-202"
        }, 
        "intervention": {
            "intervention_name": "Adefovir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Adefovir dipivoxil", 
                "Adefovir"
            ]
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "Antiviral Agents", 
            "Adenine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98122"
                }, 
                "name": "Univ of Washington"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002115"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1995"
    }, 
    "geocoordinates": {
        "Univ of Washington": "47.606 -122.332"
    }
}